Metabolomic serum abnormalities in dogs with hepatopathies

dc.accessRightsAnonymous*
dc.contributor.authorImbery, Carolin A.
dc.contributor.authorDieterle, Frank
dc.contributor.authorOttka, Claudia
dc.contributor.authorWeber, Corinna
dc.contributor.authorMüller, Elisabeth
dc.contributor.authorLohi, Hannes
dc.contributor.authorGiger, Urs
dc.contributor.authorSchlotterbeck, Götz
dc.date.accessioned2022-11-14T10:11:59Z
dc.date.available2022-10-07T10:56:18Z
dc.date.available2022-11-14T10:11:59Z
dc.date.issued2022-03-29
dc.description.abstractHepatopathies can cause major metabolic abnormalities in humans and animals. This study examined differences in serum metabolomic parameters and patterns in left-over serum samples from dogs with either congenital portosystemic shunts (cPSS, n = 24) or high serum liver enzyme activities (HLEA, n = 25) compared to control dogs (n = 64). A validated targeted proton nuclear magnetic resonance spectroscopy platform was used to assess 123 parameters. Principal component analysis of the serum metabolome demonstrated distinct clustering among individuals in each group, with the cluster of HLEA being broader compared to the other groups, presumably due to the wider spectrum of hepatic diseases represented in these samples. While younger and older adult control dogs had very similar metabolomic patterns and clusters, there were changes in many metabolites in the hepatopathy groups. Higher phenylalanine and tyrosine concentrations, lower branched-chained amino acids (BCAAs) concentrations, and altered fatty acid parameters were seen in cPSS dogs compared to controls. In contrast, dogs with HLEA had increased concentrations of BCAAs, phenylalanine, and various lipoproteins. Machine learning based solely on the metabolomics data showed excellent group classification, potentially identifying a novel tool to differentiate hepatopathies. The observed changes in metabolic parameters could provide invaluable insight into the pathophysiology, diagnosis, and prognosis of hepatopathies.en_US
dc.description.urihttps://www.nature.com/articles/s41598-022-09056-5en_US
dc.identifier.doi10.1038/s41598-022-09056-5
dc.identifier.issn2045-2322
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/33908
dc.identifier.urihttps://doi.org/10.26041/fhnw-4364
dc.issue1en_US
dc.language.isoenen_US
dc.publisherNatureen_US
dc.relation.ispartofScientific Reportsen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.subject.ddc500 - Naturwissenschaftenen_US
dc.titleMetabolomic serum abnormalities in dogs with hepatopathiesen_US
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dc.volume12en_US
dspace.entity.typePublication
fhnw.InventedHereYesen_US
fhnw.IsStudentsWorknoen_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.affiliation.hochschuleHochschule für Life Sciences FHNWde_CH
fhnw.affiliation.institutInstitut für Chemie und Bioanalytikde_CH
fhnw.openAccessCategoryGolden_US
fhnw.publicationStatePublisheden_US
relation.isAuthorOfPublication0bd5de70-5b10-46bf-aaf3-eb79c4eb10be
relation.isAuthorOfPublication.latestForDiscovery0bd5de70-5b10-46bf-aaf3-eb79c4eb10be
Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild
Name:
s41598-022-09056-5.pdf
Größe:
2.72 MB
Format:
Adobe Portable Document Format
Beschreibung:

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Kein Vorschaubild vorhanden
Name:
license.txt
Größe:
1.37 KB
Format:
Item-specific license agreed upon to submission
Beschreibung:

Versionsgeschichte

Gerade angezeigt 1 - 2 von 2
VersionDatumZusammenfassung
2*
2022-11-07 12:38:15
Lizenz und Volltext
2022-10-07 10:56:18
* Ausgewählte Version